Proven to prolong your patient’s lifeline [1]
Tarceva is the first and only oral HER1/EGFR tyrosine kinase inhibitor proven to significantly prolong survival in second-line NSCLC. Tarceva significantly increased overall survival by 37% and demonstrated significant symptom benefits by prolonging the time to progression of symptoms that affect quality of life. [1]
In exploratory subset analyses, the survival benefit achieved with second-line Tarceva extended to a broad range of patients. Similar benefits were seen in both men and women (HR=0.76 and 0.80), patients with squamous cell carcinoma and adenocarcinoma (HR=0.67 and 0.71), and in male ever smokers with squamous cell carcinoma (HR=0.66). [1,3,4]

In second-line PS 0–1 patients, Tarceva significantly prolonged overall survival by 47% vs placebo (HR=0.68; median 9.5 months vs 6.7 months). [5]

Now available in a growing number of countries worldwide, Tarceva has the power to prolong your patient’s lifeline. [1]

Convenient, once-daily tablet, with proven safety [1]

The recommended daily dose of Tarceva for NSCLC is 150 mg. Tarceva is available in three strengths—150 mg, 100 mg and 25 mg—to allow for dose reduction when necessary.* [1] Tarceva has a proven safety profile. In the pivotal Phase III trial, Tarceva was not shown to be associated with myelosuppression, neutropenia or neuropathy. [1,5] See the approval and labeling information for more on prescribing Tarceva.

*25-mg tablet not available in all countries.

Tarceva is a HER1/EGFR tyrosine kinase inhibitor [1]

Tarceva is the first and only oral HER1/EGFR tyrosine kinase inhibitor proven to significantly prolong survival in second-line NSCLC. Tarceva has a unique mechanism of action that is different from conventional chemotherapies. [1,6] Tarceva has been shown to potently inhibit Tyrosine Kinase (TK) phosphorylation of EGFR, which is expressed on the cell surfaces of normal and cancer cells. [1]

Watch how this works.

 Resources and upcoming events

To see abstracts from previous presentations and for information on upcoming congresses and events, see Physician Resources.

References: 1. Tarceva® (erlotinib) summary of product characteristics, F. Hoffmann-LaRoche Ltd., 2007. 2. Tarceva® (erlotinib) full prescribing information, OSI Pharmaceuticals, Inc., 2005. 3. Clark GM, Cameron T, Das-Gupta A. Clinical benefit of erlotinib (Tarceva®) in male smokers with squamous cell carcinoma. Poster presented at: 42nd Annual Meeting of the American Society of Clinical Oncology; June 2-6, 2006; Atlanta, Ga. Poster 7166. 4. Shepherd FA, Pereira JR, Ciuleanu T, et al, for the National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non–small-cell lung cancer. N Engl J Med. 2005;353:123-132. 5. Data on file, OSI Pharmaceuticals, Inc. 6. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer. 2004;11:689-708.

ecco